DE60011771D1 - Formulierung enthaltend testosteonundecanoat und rizinusöl - Google Patents

Formulierung enthaltend testosteonundecanoat und rizinusöl

Info

Publication number
DE60011771D1
DE60011771D1 DE60011771T DE60011771T DE60011771D1 DE 60011771 D1 DE60011771 D1 DE 60011771D1 DE 60011771 T DE60011771 T DE 60011771T DE 60011771 T DE60011771 T DE 60011771T DE 60011771 D1 DE60011771 D1 DE 60011771D1
Authority
DE
Germany
Prior art keywords
solution
liquid carrier
oil
testosteonundecanoat
risin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011771T
Other languages
English (en)
Other versions
DE60011771T2 (de
Inventor
De Henrik Nijs
Susan Chandler
Anne Perry
Josephine Joan Chri Ferdinando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE60011771D1 publication Critical patent/DE60011771D1/de
Publication of DE60011771T2 publication Critical patent/DE60011771T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60011771T 1999-04-01 2000-03-27 Formulierung enthaltend testosteonundecanoat und rizinusöl Expired - Lifetime DE60011771T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99302581 1999-04-01
EP99302581 1999-04-01
PCT/EP2000/002677 WO2000059512A1 (en) 1999-04-01 2000-03-27 Formulation comprising testosteron undecanoate and castor oil

Publications (2)

Publication Number Publication Date
DE60011771D1 true DE60011771D1 (de) 2004-07-29
DE60011771T2 DE60011771T2 (de) 2004-11-04

Family

ID=8241306

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60011771T Expired - Lifetime DE60011771T2 (de) 1999-04-01 2000-03-27 Formulierung enthaltend testosteonundecanoat und rizinusöl

Country Status (27)

Country Link
EP (1) EP1189620B1 (de)
JP (1) JP2002541111A (de)
KR (1) KR100666016B1 (de)
CN (1) CN1155385C (de)
AT (1) ATE269708T1 (de)
AU (1) AU768537B2 (de)
BR (1) BR0009465A (de)
CA (1) CA2366856C (de)
CZ (1) CZ298573B6 (de)
DE (1) DE60011771T2 (de)
DK (1) DK1189620T3 (de)
ES (1) ES2222199T3 (de)
HK (1) HK1043544A1 (de)
HU (1) HU229455B1 (de)
ID (1) ID30481A (de)
IL (2) IL145524A0 (de)
MX (1) MXPA01009919A (de)
NO (1) NO329420B1 (de)
NZ (1) NZ514290A (de)
PL (1) PL195163B1 (de)
PT (1) PT1189620E (de)
RU (1) RU2246296C2 (de)
SK (1) SK286071B6 (de)
TR (1) TR200102769T2 (de)
TW (1) TWI280124B (de)
WO (1) WO2000059512A1 (de)
ZA (1) ZA200107781B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
EP2985026B1 (de) * 2005-04-15 2022-08-03 Clarus Therapeutics, Inc. Systeme zur pharmazeutischen verabreichung hydrophober wirkstoffe und zusammensetzungen damit
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
PT2068825E (pt) 2006-10-04 2011-02-11 M & P Patent Ag Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2525520T3 (es) * 2010-04-12 2014-12-26 Clarus Therapeutics, Inc. Formulaciones orales de éster de testosterona y métodos para tratar la deficiencia de testosterona con las mismas
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
HUE037660T2 (hu) * 2011-01-26 2018-09-28 Allergan Inc Androgén készítmény szembetegség kezelésére
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
CA2950670A1 (en) 2014-06-17 2015-12-23 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
WO2015193380A2 (en) * 2014-06-19 2015-12-23 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20160193225A1 (en) * 2014-08-29 2016-07-07 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet

Also Published As

Publication number Publication date
TR200102769T2 (tr) 2002-05-21
NO20014718D0 (no) 2001-09-28
MXPA01009919A (es) 2002-04-24
NO20014718L (no) 2001-09-28
HU229455B1 (en) 2013-12-30
PL195163B1 (pl) 2007-08-31
CZ298573B6 (cs) 2007-11-14
KR20010108435A (ko) 2001-12-07
JP2002541111A (ja) 2002-12-03
ZA200107781B (en) 2002-12-20
BR0009465A (pt) 2002-01-08
DE60011771T2 (de) 2004-11-04
PT1189620E (pt) 2004-10-29
SK13722001A3 (sk) 2002-02-05
IL145524A0 (en) 2002-06-30
WO2000059512A1 (en) 2000-10-12
EP1189620B1 (de) 2004-06-23
HUP0200453A3 (en) 2003-06-30
HK1043544A1 (en) 2002-09-20
EP1189620A1 (de) 2002-03-27
ID30481A (id) 2001-12-13
SK286071B6 (sk) 2008-02-05
CZ20013507A3 (cs) 2002-03-13
TWI280124B (en) 2007-05-01
ES2222199T3 (es) 2005-02-01
HUP0200453A2 (hu) 2002-07-29
AU768537B2 (en) 2003-12-18
CN1155385C (zh) 2004-06-30
KR100666016B1 (ko) 2007-01-10
RU2246296C2 (ru) 2005-02-20
ATE269708T1 (de) 2004-07-15
IL145524A (en) 2006-12-31
CA2366856A1 (en) 2000-10-12
CN1346274A (zh) 2002-04-24
DK1189620T3 (da) 2004-08-16
PL351259A1 (en) 2003-04-07
CA2366856C (en) 2006-05-16
NZ514290A (en) 2003-08-29
AU4111100A (en) 2000-10-23
NO329420B1 (no) 2010-10-18

Similar Documents

Publication Publication Date Title
DE60011771D1 (de) Formulierung enthaltend testosteonundecanoat und rizinusöl
RU2001129362A (ru) Композиция, включающая ундеканоат тестостерона и касторовое масло
GB9907715D0 (en) Pharmaceutical compositions
NZ543250A (en) Pharmaceutical compositions for hepatitis C viral protease inhibitors
PL318560A1 (en) Novel orally administered preparations containing cyclosporin of simple composition and high bioavailability
MXPA04007699A (es) Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c.
WO2004012680B1 (en) Lipid-drug complexes in reversed liquid and liquid crystalline phases
HUP0500843A2 (hu) Fokozott biológiai hasznosulású, szájon át hatásos taxánszármazékokat tartalmazó gyógyszerkészítmények
RU94046044A (ru) Новые 7 бета -замещенные 4-аза- 5 альфа -холестан-оны в качестве ингибиторов 5 альфа -редуктазы, фармацевтическая композиция на их основе, способ ее получения
EP1165141A2 (de) Neue formulierungen mit lipid regulierenden wirkstoffen
EP1172107A4 (de) Heilmittel die sulfopyranosylacylglycerolderivate enthalten
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
KR970705997A (ko) N-{4-[2-(1, 2, 3, 4-테트라히드로-6, 7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9, 10-디히드로-5-메톡시-9-옥소-4-아크리딘 카르복사미드 화합물(gf120918a)을 포함하는 비경구 제약 조성물(parenteral pharmaceutical compositions containing gf120918a)
MXPA04000535A (es) FORMULACIONES ANTIHISTAMINICAS PARA FORMAS DE DOSIFICACION DE CaPSULAS SUAVES.
AR023235A1 (es) Formulaciones de androgenos
MXPA05008921A (es) Formulaciones orales semisolidas para liberacion inmediata que comprenden un agente hidrofobo anticancer, un glicerido poliglicolisado y un vehiculo hidrofilo.
KR20050030281A (ko) 가용성 로바스타틴의 연질캡슐제 조성물 및 그의 제조방법
TH33003B (th) สูตรตำรับแอนโดรเจน
TH60756A (th) สูตรตำรับแอนโดรเจน
US20060024341A1 (en) Microemulsion composition and related method
TH34374B (th) องค์ประกอบเชิงเภสัชกรรมชนิดที่เป็นของแข็งซึ่งประกอบด้วยอนุพันธ์เบนโซฟูแรน
TH40043A (th) องค์ประกอบเชิงเภสัชกรรมชนิดที่เป็นของแข็งซึ่งประกอบด้วยอนุพันธ์เบนโซฟูแรน
MY130474A (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
TH41464A (th) สารผสมทางเภสัชกรรม

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL

R082 Change of representative

Ref document number: 1189620

Country of ref document: EP

Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE